Montara Therapeutics closed an oversubscribed $8 million seed financing led by SV Health Investors’ Dementia Discovery Fund and co-led by Two Bear Capital, with Dolby Family Ventures and KdT Ventures participating.
UNC13A is an essential regulator of neurotransmitter release at synapses; mis-splicing is a critical RNA alteration occurring in up to 63 percent of all ALS patients and up to one-third of all FTD cases Preclinical data to be featured in a poster presentation at AD/PD 2024
Spineology raised $25 million in Series AA financing led by SV Health Investors, with participation from 1315 Capital and existing investor RC Capital.
TPN-101 treatment reduced the rate of decline of Vital Capacity by 50% compared to placebo after 24 weeks, an objective respiratory measure that correlates with mortality in patients with ALS
Alex joined SV in 2020 and is a Vice President in the biotech team. He helps form and fund companies developing transformational new medicines. Alex serves as a board observer at Alchemab, Dualitas, EyeBio and Therini, four SV created companies.
Dan joined SV as a Venture Partner in 2014 and is Executive Chairman or Director of a number of SV and DDF portfolio companies. Currently, he is Chair and Chief Executive Officer Pulmocide.
Kate co-leads SV’s biotech franchise which has a long history of building high value, successful new companies developing transformational new medicines and bringing drugs from discovery to market.
Laurence joined SV in 2016 with over 20 years of venture, biotech and pharma experience and helped establish the Dementia Discovery Fund. He represents DDF on several company boards.
The SV privacy policy describes the use and disclosure of personal data collected through its website and other means, including data about contacts, vendors, and prospective investors and employees.